|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||243.26 - 249.42|
|52-week range||200.32 - 290.20|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||13.02|
|Earnings date||16 Feb 2023|
|Forward dividend & yield||2.88 (1.18%)|
|Ex-dividend date||22 Feb 2023|
|1y target est||280.62|
In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.
McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.